After reaching an agreement with the FDA to explore the use of reactive aldehyde species as an objective sign for the treatment of dry eye disease, Aldeyra Therapeutics announced plans for a new drug application for reproxalap.
The FDA agreement is a meaningful announcement that allows Aldeyra to conduct the appropriate studies to evaluate the treatment effect of reproxalap in dry eye disease, Gary D. Novack, PhD, professor of ophthalmology at the School of Medicine at University of California, Davis, and president of PharmaLogic Development, told Ocular Surgery News.
No (Read more...)
Uncategorized